Protein nanoparticles for therapeutic protein delivery

2015 ◽  
Vol 3 (6) ◽  
pp. 787-799 ◽  
Author(s):  
L. P. Herrera Estrada ◽  
J. A. Champion

This review describes nanoparticles made from protein by self-assembly or desolvation as carriers for the delivery of therapeutic proteins.

2018 ◽  
Vol 6 (5) ◽  
pp. 763-768 ◽  
Author(s):  
Trisha Ghosh ◽  
Manasi Mantri ◽  
Zhengying Gu ◽  
Mohammad Kalantari ◽  
Meihua Yu ◽  
...  

This work reports the significance of the carbonisation temperature of mesoporous carbon hollow spheres (MCHS) in therapeutic protein delivery.


2015 ◽  
Vol 3 (43) ◽  
pp. 8477-8485 ◽  
Author(s):  
Yuting Niu ◽  
Meihua Yu ◽  
Jun Zhang ◽  
Yannan Yang ◽  
Chun Xu ◽  
...  

Silica nanoparticles with controllable surface roughness have been successfully prepared for therapeutic anti-pAkt antibody delivery.


2021 ◽  
Vol 11 (3) ◽  
pp. 253-257
Author(s):  
Arindam Chakraborty ◽  
Dipak Kumar Singha ◽  
Manas Chakraborty ◽  
Payel Mukherjee

Therapeutic protein are one of the prime option of biologicals as per their clinical uses. In recent times, uses of therapeutic protein increases day by day. Protein therapeutics are used extensively to treat various diseases like cancer, AIDS etc. Due to recent advancement in pharmaceutical biotechnology the interest towards therapeutic proteins are augmenting nowadays. Various clinical research are going on in this field to treat different diseases and pharmaceutical industries are also make interest on therapeutic proteins. Among the various treatment options therapeutic protein will provide highest chance of clinical success. Some recent clinical trials demonstrate that therapeutic protein may provide the safe and potential option to treat various diseases, but there are some drawbacks also like some immunogenic issues, safety, stability problem of protein, degradation of protein in various conditions.


2012 ◽  
Vol 30 (1) ◽  
pp. 269-279 ◽  
Author(s):  
Kai Shi ◽  
Fude Cui ◽  
Hongshu Bi ◽  
Yanbo Jiang ◽  
Hang Shi ◽  
...  

Polymers ◽  
2018 ◽  
Vol 10 (9) ◽  
pp. 1039 ◽  
Author(s):  
Nicholas D. Posey ◽  
Gregory N. Tew

Intracellular protein delivery is an invaluable tool for biomedical research, as it enables fundamental studies of cellular processes and creates opportunities for novel therapeutic development. Protein delivery reagents such as cell penetration peptides (CPPs) and protein transduction domains (PTDs) are frequently used to facilitate protein delivery. Herein, synthetic polymer mimics of PTDs, called PTDMs, were studied for their ability to self-assemble in aqueous media as it was not known whether self-assembly plays a role in the protein binding and delivery process. The results obtained from interfacial tensiometry (IFT), transmission electron microscopy (TEM), transmittance assays (%T), and dynamic light scattering (DLS) indicated that PTDMs do not readily aggregate or self-assemble at application-relevant time scales and concentrations. However, additional DLS experiments were used to confirm that the presence of protein is required to induce the formation of PTDM-protein complexes and that PTDMs likely bind as single chains.


RSC Advances ◽  
2014 ◽  
Vol 4 (77) ◽  
pp. 40882-40891 ◽  
Author(s):  
Hui Han ◽  
De-E Liu ◽  
Hongguang Lu ◽  
Wen-Xing Gu ◽  
Hui Gao

A pseudo-graft copolymer micelle was constructed from the self-assembly of (6-(2-aminoethyl)-amino-6-deoxy)-cyclodextrin (β-CDen)-modified poly(aspartic acid) (PASP-CD) with cholesterol-modified poly(d,l-lactide) (PLA-Chol) using host–guest inclusion complexation in water.


Author(s):  
G. Manu ◽  
Nagma Firdose ◽  
M. K. Jayanthi ◽  
Ranjith Raj ◽  
Shashank M. Patil ◽  
...  

Medicinal formulations have evolved from the use of small molecules that act by blocking various receptors. On the contrary, therapeutic proteins are a class of medicines that have gained increased popularity owing to its low toxicity, high stability and exquisite specificity. Oral delivery of protein drugs is a very interesting but a highly challenging area of medicine that requires advancements in terms of bioavailability of oral drugs. The main objective of the present review is to provide a systematic overview of the various physiological barriers of delivery of therapeutic proteins and novel approaches available in this field in order to counter these physiological barriers. Advances in terms of inhibitors of proteases, permeation enhancers, mucoadhesives, short peptide conjugates, particulate delivery system including nanoparticles. Oral therapeutic proteins face challenges with regard to oral bioavailability, stability of the protein and reproducibility. Among the various strategies, a co-administration of permeation enhancers with protease inhibitors have proven most effective, while particulate delivery system is still under clinical studies in order to be establishes as a method. Overall, a thorough and focused research with sufficient knowledge on the structure-function relationship, substrate specificity and physiological parameters can deliver a potent therapeutic protein with high efficiency.


2019 ◽  
Vol 1 (5) ◽  
pp. 1833-1846 ◽  
Author(s):  
Santiago Sosa ◽  
Andrés H. Rossi ◽  
Alan M. Szalai ◽  
Sebastián Klinke ◽  
Jimena Rinaldi ◽  
...  

In this work we rationally redesign and engineer a decameric protein scaffold to generate an asymmetric Janus-like protein nanoparticle. As a proof of concept this novel scaffold is functionalized (i) to fluorescently label eukaryotic cells and (ii) to generate a multichromophoric FRET nanoparticle.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Nhan H. Nguyen ◽  
Fiona Y. Glassman ◽  
Robert K. Dingman ◽  
Gautam N. Shenoy ◽  
Elizabeth A. Wohlfert ◽  
...  

AbstractThe safety and efficacy of several life-saving therapeutic proteins are compromised due to their immunogenicity. Once a sustained immune response against a protein-based therapy is established, clinical options that are safe and cost-effective become limited. Prevention of immunogenicity of therapeutic proteins prior to their initial use is critical as it is often difficult to reverse an established immune response. Here, we discuss a rational design and testing of a phosphatidylserine-containing nanoparticle platform for novel oral prophylactic reverse vaccination approach, i.e., pre-treatment of a therapeutic protein in the presence of nanoparticles to prevent immunogenicity of protein therapies.


2020 ◽  
Vol 04 ◽  
Author(s):  
Manu Singhai ◽  
Sankha Bhattacharya

Abstract:: Polysarcosine (psar) is a non-ionic hydrophilic polypeptoid with numerous biologically relevant properties. Polysarcosine is poly (n-methylated glycine) and has been reported first by wesley and co-workers in the 1920s. Polysarcosine was first synthesized via ring-opening polymerization (rop) of sarcosine n-carboxyanhydride, using high-vacuum techniques. Overall, findings highlight the potential of poly(sarcosine) as an alternative corona-forming polymer to poly (ethylene glycol)-based analogues of (polymerization-induced self-assembly) pisa assemblies for use in various pharmaceutical and biomedical applications. Numerous studies suggested that such polypeptoids hold enormous potential for many biomedical applications, including protein delivery, colloidal stabilization, and nanomedicine.


Sign in / Sign up

Export Citation Format

Share Document